Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arcellx Inc ( (ACLX) ) just unveiled an update.
On March 18, 2025, Arcellx, Inc. announced changes to its Board of Directors, with Derek Yoon resigning and Andrew Galligan and Kristin Myers being appointed to fill vacancies. These appointments bring significant experience to the company, with Galligan’s financial leadership and Myers’ healthcare expertise expected to support Arcellx’s strategic growth and anticipated commercial launch of its lead product candidate, anito-cel, in 2026.
More about Arcellx Inc
Arcellx, Inc. is a clinical-stage biotechnology company focused on reimagining cell therapy by developing innovative immunotherapies for patients with cancer and other incurable diseases.
YTD Price Performance: -9.40%
Average Trading Volume: 621,988
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.84B
See more data about ACLX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue